{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:08:06Z","timestamp":1792181286783,"version":"4.4.0"},"reference-count":150,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.leukres.2023.107420","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:08:58Z","timestamp":1699574938000},"page":"107420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["The molecular landscape of myeloproliferative neoplasms associated with splanchnic vein thrombosis: Current perspective"],"prefix":"10.1016","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0657-506X","authenticated-orcid":false,"given":"Carlo","family":"Pescia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Bucelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Gianelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Iurlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2023.107420_bib1","series-title":"Haematolymphoid Tumours [Internet; beta version ahead of print]","year":"2022"},{"key":"10.1016\/j.leukres.2023.107420_bib2","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107420_bib3","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ajh.26751","article-title":"The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms","volume":"98","author":"Thiele","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2023.107420_bib4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00428-022-03480-8","article-title":"International consensus classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms","volume":"482","author":"Gianelli","year":"2023","journal-title":"Virchows Arch."},{"key":"10.1016\/j.leukres.2023.107420_bib5","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.2022015853","article-title":"Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia","volume":"140","author":"Duncavage","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107420_bib6","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s00277-022-04920-w","article-title":"Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing","volume":"101","author":"Maddali","year":"2022","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2023.107420_bib7","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.3390\/ijms20081839","article-title":"Blast transformation in myeloproliferative neoplasms: risk factors, biological findings, and targeted therapeutic options","volume":"20","author":"Iurlo","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.leukres.2023.107420_bib8","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.mayocp.2017.06.002","article-title":"Genetic risk assessment in myeloproliferative neoplasms","volume":"92","author":"Tefferi","year":"2017","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.leukres.2023.107420_bib9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/VHRM.S197732","article-title":"Splanchnic vein thrombosis: current perspectives","volume":"15","author":"Valeriani","year":"2019","journal-title":"Vasc. Health Risk Manag"},{"key":"10.1016\/j.leukres.2023.107420_bib10","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.3748\/wjg.v12.i13.2115","article-title":"Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies","volume":"12","author":"Ogren","year":"2006","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.leukres.2023.107420_bib11","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1160\/TH16-10-0781","article-title":"Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome","volume":"117","author":"Ageno","year":"2017","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.leukres.2023.107420_bib12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/M17-0028","article-title":"Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms","volume":"168","author":"Hultcrantz","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.leukres.2023.107420_bib13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/ejh.13335","article-title":"Outcomes of splanchnic vein thrombosis in patients with myeloproliferative neoplasms in a single center experience","volume":"104","author":"Tremblay","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2023.107420_bib14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.thromres.2022.08.003","article-title":"Splanchnic vein thrombosis associated with myeloproliferative neoplasms","volume":"218","author":"Tremblay","year":"2022","journal-title":"Thromb. Res."},{"key":"10.1016\/j.leukres.2023.107420_bib15","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1182\/blood-2011-09-376517","article-title":"Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis","volume":"120","author":"Smalberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107420_bib16","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.leukres.2015.03.009","article-title":"Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis","volume":"39","author":"Gianelli","year":"2015","journal-title":"Leuk. Res"},{"key":"10.1016\/j.leukres.2023.107420_bib17","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.3109\/10428194.2012.759656","article-title":"Age-related differences in disease characteristics and clinical outcomes in polycythemia vera","volume":"54","author":"Stein","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2023.107420_bib18","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/bjh.13080","article-title":"A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera","volume":"167","author":"Lussana","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2023.107420_bib19","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/874146","article-title":"Gender and vascular complications in the JAK2 V617F-positive myeloproliferative neoplasms","volume":"2011","author":"Stein","year":"2011","journal-title":"Thrombosis"},{"key":"10.1016\/j.leukres.2023.107420_bib20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.thromres.2011.03.024","article-title":"Sex modulation of the occurrence of jak2 v617f mutation in patients with splanchnic venous thrombosis","volume":"128","author":"Colaizzo","year":"2011","journal-title":"Thromb. Res."},{"key":"10.1016\/j.leukres.2023.107420_bib21","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1182\/blood-2010-11-319087","article-title":"The JAK2 46\/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis","volume":"117","author":"Smalberg","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107420_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012582","article-title":"The contribution of JAK2 46\/1 haplotype in the predisposition to myeloproliferative neoplasms","volume":"23","author":"Paes","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.leukres.2023.107420_bib23","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2023.107420_bib24","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2011.063","article-title":"Causes of adult splanchnic vein thrombosis in the mediterranean area","volume":"3","author":"De Stefano","year":"2011","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"10.1016\/j.leukres.2023.107420_bib25","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/ajh.25677","article-title":"Splanchnic vein thromboses associated with myeloproliferative neoplasms: an international, retrospective study on 518 cases","volume":"95","author":"Sant'Antonio","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2023.107420_bib26","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.clml.2014.04.004","article-title":"Clinical features of patients with philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension","volume":"15","author":"Yan","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2023.107420_bib27","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","article-title":"Thrombosis in primary myelofibrosis: incidence and risk factors","volume":"115","author":"Barbui","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107420_bib28","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ejim.2015.03.009","article-title":"High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms","volume":"26","author":"Enblom","year":"2015","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.leukres.2023.107420_bib29","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.ejim.2018.03.009","article-title":"Heterogeneity among splanchnic vein thrombosis associated with myeloproliferative neoplasms","volume":"52","author":"Cattaneo","year":"2018","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.leukres.2023.107420_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.103","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients","volume":"6","author":"De Stefano","year":"2016","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2023.107420_bib31","doi-asserted-by":"crossref","DOI":"10.1186\/s12959-018-0187-z","article-title":"Splanchnic venous thrombosis in JAK2 V617F mutation positive myeloproliferative neoplasms \u2013 long term follow-up of a regional case series","volume":"16","author":"Greenfield","year":"2018","journal-title":"Thromb. J."},{"key":"10.1016\/j.leukres.2023.107420_bib32","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3324\/haematol.2020.249409","article-title":"Anemia and hemodilution: analysis of a single center cohort based on 2,858 red cell mass measurements","volume":"106","author":"Drevon","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2023.107420_bib33","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.3324\/haematol.2019.229039","article-title":"Time for revival of the red blood cell count and red cell mass in the differential diagnosis between essential thrombocythemia and polycythemia vera?","volume":"104","author":"Hasselbalch","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2023.107420_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26896","article-title":"Myeloproliferative neoplasms and splanchnic vein thrombosis: contemporary diagnostic and therapeutic strategies","author":"Kiladjian","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2023.107420_bib35","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00277-020-03965-z","article-title":"Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis","volume":"99","author":"Alvarez-Larr\u00e1n","year":"2020","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2023.107420_bib36","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/hep.28466","article-title":"Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis","volume":"63","author":"Noronha Ferreira","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.leukres.2023.107420_bib37","doi-asserted-by":"crossref","first-page":"E61","DOI":"10.1002\/ajh.24993","article-title":"Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: The Mayo clinic experience with 84 consecutive cases","volume":"93","author":"Lavu","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2023.107420_bib38","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/s41375-019-0487-8","article-title":"Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study","volume":"33","author":"Barbui","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2023.107420_bib39","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1182\/bloodadvances.2020002414","article-title":"Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses","volume":"4","author":"Debureaux","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2023.107420_bib40","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0140-6736(78)92098-6","article-title":"Vascular occlusive episodes and venous h\u00e6matocrit in primary proliferative polycyth\u00e6mlx","volume":"312","author":"Pearson","year":"1978","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2023.107420_bib41","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/blood-2008-11-191544","article-title":"The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome","volume":"113","author":"Sozer","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107420_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015277","article-title":"High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis","volume":"5","author":"Rosti","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2023.107420_bib43","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/bjh.14327","article-title":"Granulocyte whole exome sequencing and endothelial JAK2V617F in patients with JAK2V617F positive Budd-Chiari syndrome without myeloproliferative neoplasm","volume":"180","author":"Helman","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2023.107420_bib44","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1055\/s-0038-1667015","article-title":"Endothelial cells harbouring the JAK2V617F mutation display pro-adherent and pro-thrombotic features","volume":"118","author":"Guadall","year":"2018","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.leukres.2023.107420_bib45","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3324\/haematol.2018.195321","article-title":"Vascular endothelial cell expression of JAK2V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression","volume":"104","author":"Alexandre","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2023.107420_bib46","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1111\/jth.15095","article-title":"Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm","volume":"18","author":"Castiglione","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.leukres.2023.107420_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12030364","article-title":"Circulating endothelial cell levels correlate with treatment outcomes of splanchnic vein thrombosis in patients with chronic myeloproliferative neoplasms","volume":"12","author":"Giordano","year":"2022","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.leukres.2023.107420_bib48","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3109\/10715762.2013.860225","article-title":"Nitric oxide scavenging by cell-free hemoglobin may be a primary factor determining hypertension in polycythemic patients","volume":"48","author":"Rusak","year":"2014","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.leukres.2023.107420_bib49","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1038\/onc.2017.148","article-title":"STAT3 activation in endothelial cells is important for tumor metastasis via increased cell adhesion molecule expression","volume":"36","author":"Kim","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2023.107420_bib50","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.049029","article-title":"Suppressing STAT3 activity protects the endothelial barrier from VEGF-mediated vascular permeability","volume":"14","author":"Wang","year":"2021","journal-title":"Dis. Models Mech."},{"key":"10.1016\/j.leukres.2023.107420_bib51","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1034\/j.1600-0609.2002.01732.x","article-title":"Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera","volume":"69","author":"Jensen","year":"2002","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2023.107420_bib52","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/ijlh.12838","article-title":"Erythrocytes from patients with myeloproliferative neoplasms and splanchnic venous thrombosis show greater expression of Lu\/BCAM","volume":"40","author":"Novitzky-Basso","year":"2018","journal-title":"Int. J. Lab Hematol."},{"key":"10.1016\/j.leukres.2023.107420_bib53","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11899-013-0176-z","article-title":"Are MPNs vascular diseases?","volume":"8","author":"Finazzi","year":"2013","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.leukres.2023.107420_bib54","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s11899-021-00630-8","article-title":"Novel pathophysiological mechanisms of thrombosis in myeloproliferative neoplasms","volume":"16","author":"Reeves","year":"2021","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.leukres.2023.107420_bib55","doi-asserted-by":"crossref","first-page":"5617","DOI":"10.1182\/blood-2008-12-196014","article-title":"JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis","volume":"113","author":"Dentali","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107420_bib56","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s12288-020-01292-x","article-title":"JAK2V617F mutation in patient with splanchnic vein thrombosis","volume":"36","author":"Kumar","year":"2020","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"10.1016\/j.leukres.2023.107420_bib57","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1751-553X.2011.01308.x","article-title":"Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis","volume":"33","author":"Yoo","year":"2011","journal-title":"Int. J. Lab Hematol."},{"key":"10.1016\/j.leukres.2023.107420_bib58","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/2040620716680333","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease","volume":"8","author":"How","year":"2017","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.leukres.2023.107420_bib59","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2023.107420_bib60","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1002\/cam4.2886","article-title":"Thrombosis among 1537 patients with JAK2V617F-mutated myeloproliferative neoplasms: Risk factors and development of a predictive model","volume":"9","author":"Zhang","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.leukres.2023.107420_bib61","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41408-021-00581-6","article-title":"JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis","volume":"11","author":"Guglielmelli","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2023.107420_bib62","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2023.107420_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/genes12040559","article-title":"Low JAK2 V617F Allele Burden in Ph-negative chronic myeloproliferative neoplasms is associated with additional CALR or MPL gene mutations","volume":"12","author":"Makarik","year":"2021","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.leukres.2023.107420_bib64","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00277-014-2249-z","article-title":"Molecular analyses in the diagnosis of myeloproliferative neoplasm-related splanchnic vein thrombosis","volume":"94","author":"Iurlo","year":"2015","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2023.107420_bib65","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/bjh.14958","article-title":"Distinct clinical, laboratory and molecular features of myeloproliferative neoplasm patients with splanchnic vein thrombosis","volume":"183","author":"How","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2023.107420_bib66","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jhep.2020.06.045","article-title":"Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis","volume":"74","author":"Magaz","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.leukres.2023.107420_bib67","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-020-00254-9","article-title":"Ultradeep targeted sequencing reveals low allele frequencies of somatic JAK2 and MPL variants in patients with abdominal vein thromboses: results of an ongoing prospective prevalence study in Mecklenburg-West Pomerania","volume":"8","author":"Grunwald","year":"2020","journal-title":"Biomark. Res."},{"key":"10.1016\/j.leukres.2023.107420_bib68","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s11239-012-0738-2","article-title":"The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis","volume":"34","author":"Yonal","year":"2012","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.leukres.2023.107420_bib69","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1538-7836.2007.02424.x","article-title":"Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders","volume":"5","author":"De Stefano","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.leukres.2023.107420_bib70","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/hep.21489","article-title":"JAK2 mutation: The best diagnostic tool for myeloproliferative disease in splanchnic vein thrombosis?","volume":"44","author":"Janssen","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.leukres.2023.107420_bib71","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5152\/tjg.2015.5738","article-title":"Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and\/or portal vein thrombosis","volume":"26","author":"Karak\u00f6se","year":"2015","journal-title":"Turk. J. Gastroenterol."},{"key":"10.1016\/j.leukres.2023.107420_bib72","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1182\/blood-2007-11-125328","article-title":"The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases","volume":"111","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107420_bib73","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/hep.21435","article-title":"Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis","volume":"44","author":"Primignani","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.leukres.2023.107420_bib74","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.thromres.2013.07.014","article-title":"Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation","volume":"132","author":"Colaizzo","year":"2013","journal-title":"Thromb. Res."},{"key":"10.1016\/j.leukres.2023.107420_bib75","doi-asserted-by":"crossref","first-page":"457","DOI":"10.4065\/83.4.457","article-title":"JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients","volume":"83","author":"Pardanani","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.leukres.2023.107420_bib76","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2008-02-137687","article-title":"MPL and JAK2 exon 12 mutations in patients with the Budd-Chiari syndrome or extrahepatic portal vein obstruction","volume":"111","author":"Bergamaschi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107420_bib77","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/ajh.21335","article-title":"Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms","volume":"84","author":"Fiorini","year":"2009","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2023.107420_bib78","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1038\/leu.2010.172","article-title":"JAK2 46\/1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia","volume":"24","author":"Andrikovics","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2023.107420_bib79","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/leu.2009.226","article-title":"The JAK2 46\/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients","volume":"24","author":"Pardanani","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2023.107420_bib80","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3324\/haematol.2011.055392","article-title":"The JAK2 46\/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection?","volume":"96","author":"Hermouet","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2023.107420_bib81","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1538-7836.2009.03691.x","article-title":"The JAK2 rs12343867 CC genotype frequently occurs in patients with splanchnic venous thrombosis without the JAK2V617F mutation: a retrospective study","volume":"8","author":"Colaizzo","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.leukres.2023.107420_bib82","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.leukres.2011.08.008","article-title":"JAK2 46\/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms","volume":"36","author":"Villani","year":"2012","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2023.107420_bib83","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00277-014-2134-9","article-title":"The JAK2 46\/1 haplotype (GGCC) in myeloproliferative neoplasms and splanchnic vein thrombosis: a pooled analysis of 26 observational studies","volume":"93","author":"Li","year":"2014","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2023.107420_bib84","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041152","article-title":"The JAK2 GGCC (46\/1) haplotype in myeloproliferative neoplasms: causal or random?","volume":"19","author":"Anelli","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.leukres.2023.107420_bib85","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2023.107420_bib86","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.90","article-title":"Validation of the differential prognostic impact of type 1\/type 1-like versus type 2\/type 2-like CALR mutations in myelofibrosis","volume":"5","author":"Guglielmelli","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2023.107420_bib87","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jhep.2014.08.032","article-title":"Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis","volume":"62","author":"Turon","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.leukres.2023.107420_bib88","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jhep.2017.04.021","article-title":"Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: a prospective cohort study","volume":"67","author":"Poisson","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.leukres.2023.107420_bib89","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjh.13121","article-title":"Incidence of CALR mutations in patients with splanchnic vein thrombosis","volume":"168","author":"Haslam","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2023.107420_bib90","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/bjh.13235","article-title":"Detection of the CALR mutation in the diagnosis of splanchnic vein thrombosis","volume":"169","author":"Roques","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2023.107420_bib91","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.3324\/haematol.2014.120857","article-title":"Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis","volume":"100","author":"Plompen","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2023.107420_bib92","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/bjh.13314","article-title":"CALR mutations screening should not be studied in splanchnic vein thrombosis","volume":"170","author":"Castro","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2023.107420_bib93","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1182\/blood-2014-01-550434","article-title":"CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107420_bib94","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/ajh.25713","article-title":"Platelets from Calreticulin mutated essential thrombocythemia patients are less reactive than JAK2 V617F mutated platelets","volume":"95","author":"Hauschner","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2023.107420_bib95","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2015.277","article-title":"Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms","volume":"30","author":"Pietra","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2023.107420_bib96","first-page":"163","article-title":"Chapter five - the MPL mutation","volume":"vol. 365","author":"Guglielmelli","year":"2021"},{"key":"10.1016\/j.leukres.2023.107420_bib97","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26857","article-title":"Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management","author":"Tefferi","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2023.107420_bib98","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort","volume":"112","author":"Beer","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107420_bib99","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1160\/TH14-12-1055","article-title":"Clinical utility of screening for CALR gene exon 9 mutations in patients with splanchnic venous thrombosis","volume":"113","author":"Colaizzo","year":"2015","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.leukres.2023.107420_bib100","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1111\/j.1478-3231.2012.02851.x","article-title":"Non conventional mutations associated with myeloproliferative disorders are absent in splanchnic venous thrombosis cases","volume":"32","author":"Jadli","year":"2012","journal-title":"Liver Int."},{"key":"10.1016\/j.leukres.2023.107420_bib101","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jmoldx.2013.07.006","article-title":"Detection of MPL mutations by a novel allele-specific PCR-based strategy","volume":"15","author":"Furtado","year":"2013","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.leukres.2023.107420_bib102","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3343\/alm.2016.36.4.291","article-title":"Screening PCR versus sanger sequencing: detection of CALR mutations in patients with thrombocytosis","volume":"36","author":"Jeong","year":"2016","journal-title":"Ann. Lab Med"},{"key":"10.1016\/j.leukres.2023.107420_bib103","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11899-019-00514-y","article-title":"Next-generation sequencing in myeloproliferative neoplasms: is this indicated in all patients?","volume":"14","author":"Mina","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.leukres.2023.107420_bib104","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00277-018-3499-y","article-title":"Next-generation sequencing for JAK2 mutation testing: advantages and pitfalls","volume":"98","author":"Maslah","year":"2019","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2023.107420_bib105","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00277-021-04561-5","article-title":"Next-generation sequencing redefines the diagnosis of triple-negative myeloproliferative neoplasms","volume":"101","author":"Wu","year":"2022","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2023.107420_bib106","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s11899-019-00534-8","article-title":"Philadelphia-negative myeloproliferative neoplasms: laboratory workup in the era of next-generation sequencing","volume":"14","author":"Zuo","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.leukres.2023.107420_bib107","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jhep.2020.06.045","article-title":"Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis","volume":"74","author":"Magaz","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.leukres.2023.107420_bib108","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040934","article-title":"Thrombotic risk detection in patients with polycythemia vera: the predictive role of DNMT3A\/TET2\/ASXL1 mutations","volume":"12","author":"Segura-D\u00edaz","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.leukres.2023.107420_bib109","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/lt.23443","article-title":"Prevalence and clinical outcomes of the 46\/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in Budd-Chiari syndrome and their impact on thrombotic complications post liver transplantation","volume":"18","author":"Westbrook","year":"2012","journal-title":"Liver Transpl."},{"key":"10.1016\/j.leukres.2023.107420_bib110","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/j.1538-7836.2010.03810.x","article-title":"New TET2 gene mutations in patients with myeloproliferative neoplasms and splanchnic vein thrombosis","volume":"8","author":"Colaizzo","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.leukres.2023.107420_bib111","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-023-05217-2","article-title":"Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort","author":"Cattaneo","year":"2023","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2023.107420_bib112","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jhep.2020.07.043","article-title":"Benefits of molecular profiling with next-generation sequencing for the diagnosis and prognosis of myeloproliferative neoplasms in splanchnic vein thrombosis","volume":"74","author":"Kiladjian","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.leukres.2023.107420_bib113","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and Personalized Prognosis in Myeloproliferative Neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2023.107420_bib114","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1160\/th15-04-0326","article-title":"Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment","volume":"115","author":"De Stefano","year":"2016","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.leukres.2023.107420_bib115","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.trsl.2020.04.012","article-title":"Venous thrombosis of the liver: current and emerging concepts in management","volume":"225","author":"Naymagon","year":"2020","journal-title":"Transl. Res."},{"key":"10.1016\/j.leukres.2023.107420_bib116","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0168-8278(02)00434-8","article-title":"Budd-Chiari syndrome: a review by an expert panel","volume":"38","author":"Janssen","year":"2003","journal-title":"J. Hepatol."},{"key":"10.1016\/j.leukres.2023.107420_bib117","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1478-3231.2006.01269.x","article-title":"Consensus on extra-hepatic portal vein obstruction","volume":"26","author":"Sarin","year":"2006","journal-title":"Liver Int."},{"key":"10.1016\/j.leukres.2023.107420_bib118","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1182\/bloodadvances.2019001310","article-title":"The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis","volume":"4","author":"Naymagon","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2023.107420_bib119","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1038\/s41375-021-01279-1","article-title":"Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients","volume":"35","author":"Barbui","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2023.107420_bib120","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/jth.14836","article-title":"Anticoagulant therapy for splanchnic vein thrombosis","volume":"18","author":"Di Nisio","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.leukres.2023.107420_bib121","first-page":"99","article-title":"Antithrombotic treatment of splanchnic vein thrombosis: results of an international registry","volume":"40","author":"Ageno","year":"2014","journal-title":"Semin Thromb. Hemost."},{"key":"10.1016\/j.leukres.2023.107420_bib122","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.leukres.2023.107420_bib123","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","article-title":"Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry","volume":"9","author":"Kaifie","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2023.107420_bib124","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1053\/j.gastro.2017.04.042","article-title":"Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis","volume":"153","author":"Loffredo","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.leukres.2023.107420_bib125","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1053\/j.gastro.2021.09.004","article-title":"AGA technical review on coagulation in cirrhosis","volume":"161","author":"Intagliata","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.leukres.2023.107420_bib126","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.cgh.2012.01.012","article-title":"Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis","volume":"10","author":"Delgado","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.leukres.2023.107420_bib127","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.cgh.2017.10.016","article-title":"Harmful and beneficial effects of anticoagulants in patients with cirrhosis and portal vein thrombosis","volume":"16","author":"La Mura","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.leukres.2023.107420_bib128","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.leukres.2023.107420_bib129","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1002\/hep.31915","article-title":"TIPS for adults without cirrhosis with chronic mesenteric venous thrombosis and EHPVO refractory to standard-of-care therapy","volume":"74","author":"Knight","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.leukres.2023.107420_bib130","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s11239-020-02052-4","article-title":"Portal vein thrombosis patients harboring JAK2V617F have poor long-term outcomes despite anticoagulation","volume":"50","author":"Naymagon","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.leukres.2023.107420_bib131","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2023.107420_bib132","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-018-0100-9","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018","volume":"8","author":"Finazzi","year":"2018","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2023.107420_bib133","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2023.107420_bib134","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107420_bib135","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1365-2141.2009.08019.x","article-title":"A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process","volume":"148","author":"Barosi","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2023.107420_bib136","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-07-442012","article-title":"Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon \u03b1-2a","volume":"122","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107420_bib137","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2023.107420_bib138","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2023.107420_bib139","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1007\/s11864-023-01099-8","article-title":"Essential thrombocythemia in adolescents and young adults: clinical aspects, treatment options and unmet medical needs","volume":"24","author":"Iurlo","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.leukres.2023.107420_bib140","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1056\/NEJMc1401255","article-title":"Interferon alfa therapy in CALR-mutated essential thrombocythemia","volume":"371","author":"Cassinat","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2023.107420_bib141","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107420_bib142","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.leu.2404473","article-title":"A unified definition of clinical resistance\/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group","volume":"21","author":"Barosi","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2023.107420_bib143","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107420_bib144","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1182\/blood-2010-06-293415","article-title":"Dynamic international prognostic scoring system (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis","volume":"116","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107420_bib145","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2023.107420_bib146","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ajh.24614","article-title":"Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms","volume":"92","author":"Pieri","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2023.107420_bib147","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1002\/1097-0142(19911115)68:10<2310::AID-CNCR2820681034>3.0.CO;2-2","article-title":"An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression","volume":"68","author":"Barosi","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2023.107420_bib148","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.leukres.2013.09.008","article-title":"Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper","volume":"38","author":"Barosi","year":"2014","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2023.107420_bib149","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-018-0151-y","article-title":"Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases","volume":"8","author":"De Stefano","year":"2018","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2023.107420_bib150","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1038\/s41375-019-0524-7","article-title":"A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis","volume":"33","author":"Mascarenhas","year":"2019","journal-title":"Leukemia"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623006859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623006859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:04:39Z","timestamp":1758935079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212623006859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":150,"alternative-id":["S0145212623006859"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107420","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The molecular landscape of myeloproliferative neoplasms associated with splanchnic vein thrombosis: Current perspective","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107420","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107420"}}